Camrelizumab plus platinum-irinotecan followed by maintenance camrelizumab plus apatinib in untreated extensive-stage small-cell lung cancer: a nonrandomized clinical trial

BACKGROUND: Programmed cell death-ligand 1 (PD-L1) inhibitors plus chemotherapy have made substantial progress in extensive-stage small-cell lung cancer (ES-SCLC), but the survival benefit is still limited. This study aimed to evaluate the preliminary efficacy and safety of camrelizumab plus platinu...

Descripción completa

Detalles Bibliográficos
Autores principales: Ni, Jun, Si, Xiaoyan, Wang, Hanping, Zhang, Xiaotong, Zhang, Li
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10126331/
https://www.ncbi.nlm.nih.gov/pubmed/37114054
http://dx.doi.org/10.3389/fimmu.2023.1168879

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10126331/
https://www.ncbi.nlm.nih.gov/pubmed/37114054
http://dx.doi.org/10.3389/fimmu.2023.1168879

Ejemplares similares